Roche reveals new safety data for haemophilia treatment Hemlibra
No new safety signals identified with longer-term Hemlibra treatment in adult and adolescent patients
Read More
Tag: Hemlibra
NHS to reimburse Hemlibra
The ‘life-changing’ drug will be reimbursed for certain people with severe congenital haemophilia A.
Read More
Roche presents positive late-stage Hemlibra data
Haemophilia A is an inherited, serious disorder in which a person’s blood does not clot properly.
Read More
EC extends license for Roche/Chugai’s Hemlibra
The European Commission has approved Roche and Chugai Pharma UK’s Hemlibra for the prevention of bleeding episodes in people with severe haemophilia A without factor VIII inhibitors, expanding the drug’s treatment scope.
Read More
Roche’s Hemlibra shows sustained bleed control in children
Roche’s Hemlibra has shown sustained bleed control in a late-stage trial involving 85 children with haemophilia A.
Read More
Use of Roche’s haemophilia A therapy Hemlibra expanded in the US
Roche’s Hemlibra has been approved in the US for routine prophylaxis of bleeding episodes patients with haemophilia A without factor VIII inhibitors.
Read More
NHS England clears specialised treatments for NHS use
NHS England has approved routine funding for a stream of new specialised treatments, including stroke-reducing heart implants and a life changing surgical procedure for children with cerebral palsy.
Read More
Priority review for Roche’s Hemlibra
Roche’s Hemlibra will get a speedy review in the US for adults and children with haemophilia A without factor VIII inhibitors.
Read More
Trial findings back wider use of Roche’s Hemlibra
Data from two late-stage studies further support use of Roche’s Hemlibra in a much broader population of haemophilia patients.
Read More
Roche/Chugai’s Hemlibra wins green light for bleeding disorder
The European Commission has licensed Roche/Chugai’s Hemlibra for the routine prevention of bleeding episodes in patients with haemophilia A with factor VIII inhibitors.
Read More
Seven medicines leap closer to EU approval
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has put forward seven new medicines for approval in the region, including new treatment options for haemophilia A, diabetes, and a very rare genetic disorder.
Read More
Roche’s Hemlibra reduces bleeds in haemophilia A patients
Roche’s Hemlibra has hit key targets in a Phase III trial assessing its effectiveness in preventing bleeds in adults and adolescents with haemophilia A without inhibitors to factor VIII.
Read More
- NHS reduces long waits for cancer care and achieves faster ambulance responses
- MHRA’s AI Airlock to address challenges for regulating AI medical devices
- Oregon and Lantern collaborate to develop drug candidate for various cancer indications
- OneChain’s CAR T trial treats its first cortical T-cell ALL patient
- Johns Hopkins scientists depict molecular pathway to track replication in cancer cells
